Literature DB >> 26271058

Why Optimal Medical Therapy Should Be a Universal Standard of Care.

David J Maron1, William E Boden2.   

Abstract

Entities:  

Keywords:  coronary artery bypass; coronary artery disease; diabetes mellitus; percutaneous coronary intervention; risk factors

Mesh：

Year:  2015        PMID： 26271058      PMCID： PMC4695209          DOI： 10.1016/j.jacc.2015.06.018

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  10 in total

1.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  Stephan D Fihn; Julius M Gardin; Jonathan Abrams; Kathleen Berra; James C Blankenship; Apostolos P Dallas; Pamela S Douglas; Joanne M Foody; Thomas C Gerber; Alan L Hinderliter; Spencer B King; Paul D Kligfield; Harlan M Krumholz; Raymond Y K Kwong; Michael J Lim; Jane A Linderbaum; Michael J Mack; Mark A Munger; Richard L Prager; Joseph F Sabik; Leslee J Shaw; Joanna D Sikkema; Craig R Smith; Sidney C Smith; John A Spertus; Sankey V Williams
Journal:  J Am Coll Cardiol       Date:  2012-11-19       Impact factor: 24.094

2.  Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.

Authors:  William B Borden; Rita F Redberg; Alvin I Mushlin; David Dai; Lisa A Kaltenbach; John A Spertus
Journal:  JAMA       Date:  2011-05-11       Impact factor: 56.272

3.  Optimal medical therapy with or without PCI for stable coronary disease.

Authors:  William E Boden; Robert A O'Rourke; Koon K Teo; Pamela M Hartigan; David J Maron; William J Kostuk; Merril Knudtson; Marcin Dada; Paul Casperson; Crystal L Harris; Bernard R Chaitman; Leslee Shaw; Gilbert Gosselin; Shah Nawaz; Lawrence M Title; Gerald Gau; Alvin S Blaustein; David C Booth; Eric R Bates; John A Spertus; Daniel S Berman; G B John Mancini; William S Weintraub
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

4.  Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-up.

Authors:  Javaid Iqbal; Yao-Jun Zhang; David R Holmes; Marie-Claude Morice; Michael J Mack; Arie Pieter Kappetein; Ted Feldman; Elizabeth Stahle; Javier Escaned; Adrian P Banning; Julian P Gunn; Antonio Colombo; Ewout W Steyerberg; Friedrich W Mohr; Patrick W Serruys
Journal:  Circulation       Date:  2015-02-24       Impact factor: 29.690

5.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

6.  Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

Authors:  W L Haskell; E L Alderman; J M Fair; D J Maron; S F Mackey; H R Superko; P T Williams; I M Johnstone; M A Champagne; R M Krauss
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

7.  Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.

Authors:  Bernard De Bruyne; Nico H J Pijls; Bindu Kalesan; Emanuele Barbato; Pim A L Tonino; Zsolt Piroth; Nikola Jagic; Sven Möbius-Winkler; Sven Mobius-Winckler; Gilles Rioufol; Nils Witt; Petr Kala; Philip MacCarthy; Thomas Engström; Keith G Oldroyd; Kreton Mavromatis; Ganesh Manoharan; Peter Verlee; Ole Frobert; Nick Curzen; Jane B Johnson; Peter Jüni; William F Fearon
Journal:  N Engl J Med       Date:  2012-08-27       Impact factor: 91.245

8.  Risk factor control for coronary artery disease secondary prevention in large randomized trials.

Authors:  Michael E Farkouh; William E Boden; Vera Bittner; Victoria Muratov; Pamela Hartigan; May Ogdie; Marnie Bertolet; Shiny Mathewkutty; Koon Teo; David J Maron; Sanjum S Sethi; Michael Domanski; Robert L Frye; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2013-04-16       Impact factor: 24.094

9.  A randomized trial of therapies for type 2 diabetes and coronary artery disease.

Authors:  Robert L Frye; Phyllis August; Maria Mori Brooks; Regina M Hardison; Sheryl F Kelsey; Joan M MacGregor; Trevor J Orchard; Bernard R Chaitman; Saul M Genuth; Suzanne H Goldberg; Mark A Hlatky; Teresa L Z Jones; Mark E Molitch; Richard W Nesto; Edward Y Sako; Burton E Sobel
Journal:  N Engl J Med       Date:  2009-06-07       Impact factor: 91.245

10.  Achievement of optimal medical therapy goals for U.S. adults with coronary artery disease: results from the REGARDS Study (REasons for Geographic And Racial Differences in Stroke).

Authors:  Todd M Brown; Jenifer H Voeks; Vera Bittner; David A Brenner; Mary Cushman; David C Goff; Stephen Glasser; Paul Muntner; Paul B Tabereaux; Monika M Safford
Journal:  J Am Coll Cardiol       Date:  2014-02-26       Impact factor: 24.094
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.